Next Oncology

Irving, Texas 75039

8 studies enrolling now · 17 studies all time

What they study most

Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, Advanced-stage Solid Tumors, Breast Cancer, Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Colorectal Cancer, Endometrial Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), GEJ Adenocarcinoma

Studies at this site

• A Phase 1 Study of IM-1021 in Participants With Advanced Cancer — Recruiting now
• A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors — Recruiting now
• AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors — Recruiting now
• A 2-part Phase 1/2 Open-label Trial on ODM-212 — Recruiting now
• Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors — Recruiting now
• A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies — Recruiting now
• PAS-004 in Patients With Advanced Solid Tumors — Recruiting now
• A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. — Recruiting now
• Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors — Recruiting now
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — Running, not enrolling
• Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications — Stopped early
• A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors — Completed
• Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors — Running, not enrolling
• Study of PYX-106 in Solid Tumors — Running, not enrolling
• CLN-418 Study on Subjects With Advanced Solid Tumors — Completed
• Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. — Stopped early
• A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors — Running, not enrolling